← All trials
NCT05745727
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Feb 27, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ProtalixLead sponsor
- New Zealand Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.